Heron Therapeutics (HRTX) Inventory Average (2016 - 2026)

Heron Therapeutics (HRTX) has reported Inventory Average for 11 consecutive years, with $91.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Inventory Average rose 40.98% year-over-year to $91.6 million; the trailing twelve-month figure through Jun 2026 stood at $91.6 million (up 40.98% YoY), and the FY2025 full-year result was $73.0 million, up 53.15% from the prior year.
• Inventory Average eased to $91.6 million in Q2 2026 per HRTX's latest filing, from $92.6 million in the prior quarter.
• Across five years, Inventory Average topped out at $92.6 million in Q1 2026 and bottomed at $42.1 million in Q4 2023.
• Historically, Inventory Average has averaged $58.0 million across 5 years, with a median of $53.4 million in 2022.
• The sharpest annual moves came in 2023 and 2026: Inventory Average decreased 23.71% in 2023, then soared 68.3% in 2026.
• Over 5 years, Inventory Average stood at $53.4 million in 2022, then dropped by 21.25% to $42.1 million in 2023, then increased by 17.82% to $49.6 million in 2024, then soared by 64.23% to $81.4 million in 2025, then climbed by 12.5% to $91.6 million in 2026.
• According to Business Quant data, Inventory Average over the past three periods registered $91.6 million, $92.6 million, and $81.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.